Efficacy of Rifaximin, a Nonabsorbed Oral Antibiotic, in the Treatment of Small Intestinal Bacterial Overgrowth
Rifamixin is an orally administrated, nonabsorbed antibiotic whose utility in eradication of small intestinal bacterial overgrowth (SIBO) is currently being evaluated. The aim of this study was to investigate efficacy and safety of rifaximin in relieving symptoms and normalizing the glucose breath t...
Gespeichert in:
| Veröffentlicht in: | The American journal of the medical sciences 2007-05, Vol.333 (5), p.266-270 |
|---|---|
| Hauptverfasser: | , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 270 |
|---|---|
| container_issue | 5 |
| container_start_page | 266 |
| container_title | The American journal of the medical sciences |
| container_volume | 333 |
| creator | Majewski, Marek Reddymasu, Savio C. Sostarich, Sandra Foran, Pernilla McCallum, Richard W. |
| description | Rifamixin is an orally administrated, nonabsorbed antibiotic whose utility in eradication of small intestinal bacterial overgrowth (SIBO) is currently being evaluated.
The aim of this study was to investigate efficacy and safety of rifaximin in relieving symptoms and normalizing the glucose breath test (GBT) in patients with SIBO.
Symptom score assessment, consisting of frequency and severity of bloating, gas, abdominal pain, and bowel movements and the GBT were performed before and after treatment with rifaximin 800mg/d for 4weeks.
Twenty consecutive symptomatic patients (16 women and 4 men; mean age, 47.8years; range, 19 to 85years) who had a positive GBT were prospectively studied in an open-labeled fashion. Fourteen patients (70.0%) presented with diarrhea, 3 (15.0%) with bloating and gas, and 3 (15.0%) with constipation as the dominant symptom.
Eleven patients were hydrogen producers, 8 exclusively methane, and 1 patient produced both gases by the GBT. Among patients with diarrhea, 12 of 14 (85.7%) reported improvement in symptom scores of more than 50%; 1 between 25% and 50%, 1 had no response after 4weeks of rifamixin. Among patients with bloating and gas or constipation as the main symptom: 2 of 6 (33.3%) had improvement between 50% and 75%; 3 (50%) had 25% to 50% improvement, and 1 (16.7%) had no response. Repeat GBT at the end of the 4weeks showed that 54.5% of hydrogen formers and 50.0% of methane producers were eradicated, and there was a significant reduction (P |
| doi_str_mv | 10.1097/MAJ.0b013e3180536784 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_746010943</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0002962915325660</els_id><sourcerecordid>70512758</sourcerecordid><originalsourceid>FETCH-LOGICAL-c488t-3dc9b22bcc92f3f3b9482c9f98a7ccbe45acd6462b0d358d47f44924f9015f783</originalsourceid><addsrcrecordid>eNp9kU9rVDEUxYModlr9BiLZqJtOzb_3kmwKY6laqQ5oXT-S-xIbeS-pSaa1394MM1Bw0dW9i985HM5B6BUlJ5Ro-f7r6ssJsYRyx6kiHe-lEk_QgnZcLZnW5ClaEELYUvdMH6DDUn4TQpmi_Dk6oLIjHe37BUrn3gcwcI-Tx9-DN3_DHOIxNvhbisaWlK0b8TqbCa9iDTakGuAYh4jrtcNX2Zk6u1i36h-zmSZ8EasrNcQm-GCguhzat751-VdOd_X6BXrmzVTcy_09Qj8_nl-dfV5erj9dnK0ulyCUqks-graMWQDNPPfcaqEYaK-VkQDWic7A2IueWTLyTo1CeiE0E14T2nmp-BF6t_O9yenPpiUa5lDATZOJLm3KIEVPWo2CN_Lt42Rrisluayl2IORUSnZ-uMlhNvl-oGTYTjK0SYb_J2my13v_jZ3d-CDab9CAN3vAFDCTzyZCKA-ckkpSpht3uuNc6-02uDwUCC6CG0N2UIcxhceT_AN6OKig</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>70512758</pqid></control><display><type>article</type><title>Efficacy of Rifaximin, a Nonabsorbed Oral Antibiotic, in the Treatment of Small Intestinal Bacterial Overgrowth</title><source>MEDLINE</source><source>Journals@Ovid Ovid Autoload</source><source>Alma/SFX Local Collection</source><creator>Majewski, Marek ; Reddymasu, Savio C. ; Sostarich, Sandra ; Foran, Pernilla ; McCallum, Richard W.</creator><creatorcontrib>Majewski, Marek ; Reddymasu, Savio C. ; Sostarich, Sandra ; Foran, Pernilla ; McCallum, Richard W.</creatorcontrib><description>Rifamixin is an orally administrated, nonabsorbed antibiotic whose utility in eradication of small intestinal bacterial overgrowth (SIBO) is currently being evaluated.
The aim of this study was to investigate efficacy and safety of rifaximin in relieving symptoms and normalizing the glucose breath test (GBT) in patients with SIBO.
Symptom score assessment, consisting of frequency and severity of bloating, gas, abdominal pain, and bowel movements and the GBT were performed before and after treatment with rifaximin 800mg/d for 4weeks.
Twenty consecutive symptomatic patients (16 women and 4 men; mean age, 47.8years; range, 19 to 85years) who had a positive GBT were prospectively studied in an open-labeled fashion. Fourteen patients (70.0%) presented with diarrhea, 3 (15.0%) with bloating and gas, and 3 (15.0%) with constipation as the dominant symptom.
Eleven patients were hydrogen producers, 8 exclusively methane, and 1 patient produced both gases by the GBT. Among patients with diarrhea, 12 of 14 (85.7%) reported improvement in symptom scores of more than 50%; 1 between 25% and 50%, 1 had no response after 4weeks of rifamixin. Among patients with bloating and gas or constipation as the main symptom: 2 of 6 (33.3%) had improvement between 50% and 75%; 3 (50%) had 25% to 50% improvement, and 1 (16.7%) had no response. Repeat GBT at the end of the 4weeks showed that 54.5% of hydrogen formers and 50.0% of methane producers were eradicated, and there was a significant reduction (P <0.05) in the area under the concentration-time curve and peak values. No adverse effects were observed.
Rifaximin in a dose of 800mg per day for 4weeks: 1) was safe and effective treatment in reducing symptoms in patients with SIBO of multiple etiologies, especially when diarrhea was the dominant symptom; and 2) normalized the GBT in approximately 50% of patients. Data support a future therapeutic role for rifaximin in SIBO.</description><identifier>ISSN: 0002-9629</identifier><identifier>EISSN: 1538-2990</identifier><identifier>DOI: 10.1097/MAJ.0b013e3180536784</identifier><identifier>PMID: 17505166</identifier><identifier>CODEN: AJMSA9</identifier><language>eng</language><publisher>Hagerstown, MD: Elsevier Inc</publisher><subject>Adult ; Aged ; Aged, 80 and over ; Anti-Infective Agents - therapeutic use ; Antibacterial agents ; Antibiotics. Antiinfectious agents. Antiparasitic agents ; Bacteria ; Bacterial Infections - drug therapy ; Biological and medical sciences ; Breath Tests ; Female ; Gastrointestinal Agents - therapeutic use ; Gastrointestinal Diseases - drug therapy ; Gastrointestinal Diseases - microbiology ; General aspects ; Glucose breath test (GBT) ; Humans ; Hydrogen - metabolism ; Intestine, Small - microbiology ; Male ; Medical sciences ; Methane - metabolism ; Middle Aged ; Pharmacology. Drug treatments ; Rifamixin ; Rifamycins - therapeutic use ; Small intestinal bacterial overgrowth (SIBO) ; Treatment Outcome</subject><ispartof>The American journal of the medical sciences, 2007-05, Vol.333 (5), p.266-270</ispartof><rights>2007 Southern Society for Clinical Investigation</rights><rights>2007 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c488t-3dc9b22bcc92f3f3b9482c9f98a7ccbe45acd6462b0d358d47f44924f9015f783</citedby><cites>FETCH-LOGICAL-c488t-3dc9b22bcc92f3f3b9482c9f98a7ccbe45acd6462b0d358d47f44924f9015f783</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27923,27924</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=18787129$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/17505166$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Majewski, Marek</creatorcontrib><creatorcontrib>Reddymasu, Savio C.</creatorcontrib><creatorcontrib>Sostarich, Sandra</creatorcontrib><creatorcontrib>Foran, Pernilla</creatorcontrib><creatorcontrib>McCallum, Richard W.</creatorcontrib><title>Efficacy of Rifaximin, a Nonabsorbed Oral Antibiotic, in the Treatment of Small Intestinal Bacterial Overgrowth</title><title>The American journal of the medical sciences</title><addtitle>Am J Med Sci</addtitle><description>Rifamixin is an orally administrated, nonabsorbed antibiotic whose utility in eradication of small intestinal bacterial overgrowth (SIBO) is currently being evaluated.
The aim of this study was to investigate efficacy and safety of rifaximin in relieving symptoms and normalizing the glucose breath test (GBT) in patients with SIBO.
Symptom score assessment, consisting of frequency and severity of bloating, gas, abdominal pain, and bowel movements and the GBT were performed before and after treatment with rifaximin 800mg/d for 4weeks.
Twenty consecutive symptomatic patients (16 women and 4 men; mean age, 47.8years; range, 19 to 85years) who had a positive GBT were prospectively studied in an open-labeled fashion. Fourteen patients (70.0%) presented with diarrhea, 3 (15.0%) with bloating and gas, and 3 (15.0%) with constipation as the dominant symptom.
Eleven patients were hydrogen producers, 8 exclusively methane, and 1 patient produced both gases by the GBT. Among patients with diarrhea, 12 of 14 (85.7%) reported improvement in symptom scores of more than 50%; 1 between 25% and 50%, 1 had no response after 4weeks of rifamixin. Among patients with bloating and gas or constipation as the main symptom: 2 of 6 (33.3%) had improvement between 50% and 75%; 3 (50%) had 25% to 50% improvement, and 1 (16.7%) had no response. Repeat GBT at the end of the 4weeks showed that 54.5% of hydrogen formers and 50.0% of methane producers were eradicated, and there was a significant reduction (P <0.05) in the area under the concentration-time curve and peak values. No adverse effects were observed.
Rifaximin in a dose of 800mg per day for 4weeks: 1) was safe and effective treatment in reducing symptoms in patients with SIBO of multiple etiologies, especially when diarrhea was the dominant symptom; and 2) normalized the GBT in approximately 50% of patients. Data support a future therapeutic role for rifaximin in SIBO.</description><subject>Adult</subject><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Anti-Infective Agents - therapeutic use</subject><subject>Antibacterial agents</subject><subject>Antibiotics. Antiinfectious agents. Antiparasitic agents</subject><subject>Bacteria</subject><subject>Bacterial Infections - drug therapy</subject><subject>Biological and medical sciences</subject><subject>Breath Tests</subject><subject>Female</subject><subject>Gastrointestinal Agents - therapeutic use</subject><subject>Gastrointestinal Diseases - drug therapy</subject><subject>Gastrointestinal Diseases - microbiology</subject><subject>General aspects</subject><subject>Glucose breath test (GBT)</subject><subject>Humans</subject><subject>Hydrogen - metabolism</subject><subject>Intestine, Small - microbiology</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Methane - metabolism</subject><subject>Middle Aged</subject><subject>Pharmacology. Drug treatments</subject><subject>Rifamixin</subject><subject>Rifamycins - therapeutic use</subject><subject>Small intestinal bacterial overgrowth (SIBO)</subject><subject>Treatment Outcome</subject><issn>0002-9629</issn><issn>1538-2990</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2007</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kU9rVDEUxYModlr9BiLZqJtOzb_3kmwKY6laqQ5oXT-S-xIbeS-pSaa1394MM1Bw0dW9i985HM5B6BUlJ5Ro-f7r6ssJsYRyx6kiHe-lEk_QgnZcLZnW5ClaEELYUvdMH6DDUn4TQpmi_Dk6oLIjHe37BUrn3gcwcI-Tx9-DN3_DHOIxNvhbisaWlK0b8TqbCa9iDTakGuAYh4jrtcNX2Zk6u1i36h-zmSZ8EasrNcQm-GCguhzat751-VdOd_X6BXrmzVTcy_09Qj8_nl-dfV5erj9dnK0ulyCUqks-graMWQDNPPfcaqEYaK-VkQDWic7A2IueWTLyTo1CeiE0E14T2nmp-BF6t_O9yenPpiUa5lDATZOJLm3KIEVPWo2CN_Lt42Rrisluayl2IORUSnZ-uMlhNvl-oGTYTjK0SYb_J2my13v_jZ3d-CDab9CAN3vAFDCTzyZCKA-ckkpSpht3uuNc6-02uDwUCC6CG0N2UIcxhceT_AN6OKig</recordid><startdate>20070501</startdate><enddate>20070501</enddate><creator>Majewski, Marek</creator><creator>Reddymasu, Savio C.</creator><creator>Sostarich, Sandra</creator><creator>Foran, Pernilla</creator><creator>McCallum, Richard W.</creator><general>Elsevier Inc</general><general>Lippincott</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>7QL</scope><scope>7T7</scope><scope>8FD</scope><scope>C1K</scope><scope>FR3</scope><scope>P64</scope></search><sort><creationdate>20070501</creationdate><title>Efficacy of Rifaximin, a Nonabsorbed Oral Antibiotic, in the Treatment of Small Intestinal Bacterial Overgrowth</title><author>Majewski, Marek ; Reddymasu, Savio C. ; Sostarich, Sandra ; Foran, Pernilla ; McCallum, Richard W.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c488t-3dc9b22bcc92f3f3b9482c9f98a7ccbe45acd6462b0d358d47f44924f9015f783</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2007</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Anti-Infective Agents - therapeutic use</topic><topic>Antibacterial agents</topic><topic>Antibiotics. Antiinfectious agents. Antiparasitic agents</topic><topic>Bacteria</topic><topic>Bacterial Infections - drug therapy</topic><topic>Biological and medical sciences</topic><topic>Breath Tests</topic><topic>Female</topic><topic>Gastrointestinal Agents - therapeutic use</topic><topic>Gastrointestinal Diseases - drug therapy</topic><topic>Gastrointestinal Diseases - microbiology</topic><topic>General aspects</topic><topic>Glucose breath test (GBT)</topic><topic>Humans</topic><topic>Hydrogen - metabolism</topic><topic>Intestine, Small - microbiology</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Methane - metabolism</topic><topic>Middle Aged</topic><topic>Pharmacology. Drug treatments</topic><topic>Rifamixin</topic><topic>Rifamycins - therapeutic use</topic><topic>Small intestinal bacterial overgrowth (SIBO)</topic><topic>Treatment Outcome</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Majewski, Marek</creatorcontrib><creatorcontrib>Reddymasu, Savio C.</creatorcontrib><creatorcontrib>Sostarich, Sandra</creatorcontrib><creatorcontrib>Foran, Pernilla</creatorcontrib><creatorcontrib>McCallum, Richard W.</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Industrial and Applied Microbiology Abstracts (Microbiology A)</collection><collection>Technology Research Database</collection><collection>Environmental Sciences and Pollution Management</collection><collection>Engineering Research Database</collection><collection>Biotechnology and BioEngineering Abstracts</collection><jtitle>The American journal of the medical sciences</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Majewski, Marek</au><au>Reddymasu, Savio C.</au><au>Sostarich, Sandra</au><au>Foran, Pernilla</au><au>McCallum, Richard W.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Efficacy of Rifaximin, a Nonabsorbed Oral Antibiotic, in the Treatment of Small Intestinal Bacterial Overgrowth</atitle><jtitle>The American journal of the medical sciences</jtitle><addtitle>Am J Med Sci</addtitle><date>2007-05-01</date><risdate>2007</risdate><volume>333</volume><issue>5</issue><spage>266</spage><epage>270</epage><pages>266-270</pages><issn>0002-9629</issn><eissn>1538-2990</eissn><coden>AJMSA9</coden><abstract>Rifamixin is an orally administrated, nonabsorbed antibiotic whose utility in eradication of small intestinal bacterial overgrowth (SIBO) is currently being evaluated.
The aim of this study was to investigate efficacy and safety of rifaximin in relieving symptoms and normalizing the glucose breath test (GBT) in patients with SIBO.
Symptom score assessment, consisting of frequency and severity of bloating, gas, abdominal pain, and bowel movements and the GBT were performed before and after treatment with rifaximin 800mg/d for 4weeks.
Twenty consecutive symptomatic patients (16 women and 4 men; mean age, 47.8years; range, 19 to 85years) who had a positive GBT were prospectively studied in an open-labeled fashion. Fourteen patients (70.0%) presented with diarrhea, 3 (15.0%) with bloating and gas, and 3 (15.0%) with constipation as the dominant symptom.
Eleven patients were hydrogen producers, 8 exclusively methane, and 1 patient produced both gases by the GBT. Among patients with diarrhea, 12 of 14 (85.7%) reported improvement in symptom scores of more than 50%; 1 between 25% and 50%, 1 had no response after 4weeks of rifamixin. Among patients with bloating and gas or constipation as the main symptom: 2 of 6 (33.3%) had improvement between 50% and 75%; 3 (50%) had 25% to 50% improvement, and 1 (16.7%) had no response. Repeat GBT at the end of the 4weeks showed that 54.5% of hydrogen formers and 50.0% of methane producers were eradicated, and there was a significant reduction (P <0.05) in the area under the concentration-time curve and peak values. No adverse effects were observed.
Rifaximin in a dose of 800mg per day for 4weeks: 1) was safe and effective treatment in reducing symptoms in patients with SIBO of multiple etiologies, especially when diarrhea was the dominant symptom; and 2) normalized the GBT in approximately 50% of patients. Data support a future therapeutic role for rifaximin in SIBO.</abstract><cop>Hagerstown, MD</cop><pub>Elsevier Inc</pub><pmid>17505166</pmid><doi>10.1097/MAJ.0b013e3180536784</doi><tpages>5</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0002-9629 |
| ispartof | The American journal of the medical sciences, 2007-05, Vol.333 (5), p.266-270 |
| issn | 0002-9629 1538-2990 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_746010943 |
| source | MEDLINE; Journals@Ovid Ovid Autoload; Alma/SFX Local Collection |
| subjects | Adult Aged Aged, 80 and over Anti-Infective Agents - therapeutic use Antibacterial agents Antibiotics. Antiinfectious agents. Antiparasitic agents Bacteria Bacterial Infections - drug therapy Biological and medical sciences Breath Tests Female Gastrointestinal Agents - therapeutic use Gastrointestinal Diseases - drug therapy Gastrointestinal Diseases - microbiology General aspects Glucose breath test (GBT) Humans Hydrogen - metabolism Intestine, Small - microbiology Male Medical sciences Methane - metabolism Middle Aged Pharmacology. Drug treatments Rifamixin Rifamycins - therapeutic use Small intestinal bacterial overgrowth (SIBO) Treatment Outcome |
| title | Efficacy of Rifaximin, a Nonabsorbed Oral Antibiotic, in the Treatment of Small Intestinal Bacterial Overgrowth |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-11T10%3A47%3A16IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Efficacy%20of%20Rifaximin,%20a%20Nonabsorbed%20Oral%20Antibiotic,%20in%20the%20Treatment%20of%20Small%20Intestinal%20Bacterial%20Overgrowth&rft.jtitle=The%20American%20journal%20of%20the%20medical%20sciences&rft.au=Majewski,%20Marek&rft.date=2007-05-01&rft.volume=333&rft.issue=5&rft.spage=266&rft.epage=270&rft.pages=266-270&rft.issn=0002-9629&rft.eissn=1538-2990&rft.coden=AJMSA9&rft_id=info:doi/10.1097/MAJ.0b013e3180536784&rft_dat=%3Cproquest_cross%3E70512758%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=70512758&rft_id=info:pmid/17505166&rft_els_id=S0002962915325660&rfr_iscdi=true |